Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Dose-Escalation Study of AZD0530 in Advanced Solid Tumors
jRCT2080220617Phase 1
- Sponsor
- AstraZeneca
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of saracatinib in advanced nonhematological malignancy and Nonhematologic neoplasms, sponsored by AstraZeneca. Primary endpoint: Primary safety and tolerability of AZD0530.
02
Drugs
saracatinib
03
Conditions
advanced nonhematological malignancyNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080220617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220617.